about
Novel Chlamydia pneumoniae vaccine candidates confirmed by Th1-enhanced genetic immunizationCationic liposomes containing mycobacterial lipids: a new powerful Th1 adjuvant system.Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants.Antibodies to Plasmodium falciparum glycosylphosphatidylinositols: inverse association with tolerance of parasitemia in Papua New Guinean children and adults.Vaccines: past, present and future.Th1-directing adjuvants increase the immunogenicity of oligosaccharide-protein conjugate vaccines related to Streptococcus pneumoniae type 3Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles.The future of vaccination as a treatment strategy in dermatological diseases.Characterization of stability and nasal delivery systems for immunization with nanoemulsion-based vaccinesPhytol-based novel adjuvants in vaccine formulation: 1. assessment of safety and efficacy during stimulation of humoral and cell-mediated immune responsesThe combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis.Construction of monophosphoryl lipid A producing Escherichia coli mutants and comparison of immuno-stimulatory activities of their lipopolysaccharidesProtective effect of lectin from Synadenium carinatum on Leishmania amazonensis infection in BALB/c mice.Neisseria meningitidis native outer membrane vesicles containing different lipopolysaccharide glycoforms as adjuvants for meningococcal and nonmeningococcal antigens.In planta production of plant-derived and non-plant-derived adjuvants.Cytolytic CD4(+) T cells in viral immunityMontanide ISA 71 VG is Advantageous to Freund's Adjuvant in Immunization Against S. aureus Infection of Mice.The next-generation nicotine vaccine: a novel and potent hybrid nanoparticle-based nicotine vaccine.Enhancement of humoral and cellular immunity with an anti-glucocorticoid-induced tumour necrosis factor receptor monoclonal antibody.Species-dependent role of type I IFNs and IL-12 in the CTL response induced by humanized CpG complexed with β-glucan.
P2860
Q33653680-25AA17D1-4906-4E58-B248-74F9AEE3B670Q34034287-976AADA2-D6C2-472E-8859-C9F17CFE210EQ34120040-10A3E37C-2395-4E91-9FAF-E9DD9C9BE3B1Q34130971-1828D355-76CD-4D9A-B738-EEB6E4ED07FDQ34409178-527C3C00-F20A-4991-8651-949984C51F4FQ34941564-3539EDBC-0EA7-4379-BFC5-457D2072C969Q34980516-60CD5F90-42EC-46BD-BA24-773171DE893EQ35015879-814FA132-9E5E-45A7-92AA-D55074A60778Q35049480-5CC131FA-9DC0-447A-BC54-EAA569ADC137Q35127314-26A0BFC6-A2D7-4562-9216-30092B120920Q35689134-5A330EF8-3ADD-4C7C-AD68-BD369504DA0EQ36806692-8320A41F-81B8-4E59-B4DE-760C4F5EFAB3Q36868147-EB4729FF-D391-42FD-8296-7829E564EFDEQ37545048-AA8EBB80-D4EE-40EC-A117-B526BB2DDC72Q37776716-FFF1B289-EB6F-4F94-BB51-DB883BBA2120Q37812127-CA8A668E-3726-4CBD-B04E-E8B0467B8D48Q41479231-5E410A22-C0DA-48C6-B150-CFF8331F22E0Q42627924-136A0F12-E179-4137-A6BA-ED40FC332DD3Q44267619-C37E2C0F-AFD1-4DDB-AD59-1DE3156A4003Q46608381-DFDB1BF0-F479-4BDC-8A0C-56451E8CC402
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Towards the rational design of Th1 adjuvants.
@ast
Towards the rational design of Th1 adjuvants.
@en
Towards the rational design of Th1 adjuvants.
@nl
type
label
Towards the rational design of Th1 adjuvants.
@ast
Towards the rational design of Th1 adjuvants.
@en
Towards the rational design of Th1 adjuvants.
@nl
prefLabel
Towards the rational design of Th1 adjuvants.
@ast
Towards the rational design of Th1 adjuvants.
@en
Towards the rational design of Th1 adjuvants.
@nl
P2093
P1433
P1476
Towards the rational design of Th1 adjuvants.
@en
P2093
Haensler J
Lindberg A
Moingeon P
P304
P356
10.1016/S0264-410X(01)00193-1
P407
P577
2001-08-01T00:00:00Z